- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04684719
Sang total de type O et évaluation de l'âge lors d'un essai de réanimation préhospitalière (TOWAR)
Sang total de type O et évaluation de l'âge pendant l'essai de réanimation préhospitalière (TOWAR)
Open label, multi-center, pre-hospital randomized trial utilizing 10 level-1 trauma centers designed to determine the efficacy and safety of low titer whole blood resuscitation as compared to component blood resuscitation in patients at risk of hemorrhagic shock and to appropriately characterize the hemostatic competency of whole blood relative to its age.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- University of Alabama at Birmingham
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40292
- University of Louisville
-
-
Mississippi
-
Jackson, Mississippi, États-Unis, 39216
- University of Mississippi Medical Center (UMMC)
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45267
- University of Cincinatti
-
Cleveland, Ohio, États-Unis, 44109
- Metrohealth Systems
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15213
- University of Pittsburgh
-
-
Tennessee
-
Knoxville, Tennessee, États-Unis, 37920
- University of Tennessee Medical Center
-
Nashville, Tennessee, États-Unis, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- University of Texas Health Science Center at Houston
-
-
Washington
-
Seattle, Washington, États-Unis, 98104
- University of Washington
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
1.) Injured patients at risk of hemorrhagic shock being transported from scene or referral hospital to a participating TOWAR trial site that meet requirements for initiation of blood or blood component transfusion
AND
2A.) Systolic blood pressure ≤ 90mmHg and tachycardia (HR ≥ 108) at scene, at outside hospital or during transport OR
2B.) Systolic blood pressure ≤ 70mmHg at scene, at outside hospital or during transport
Exclusion Criteria:
- Wearing NO TOWAR opt-out bracelet
- Age > 90 or < 18 years of age
- Isolated fall from standing injury mechanism
- Known prisoner or known pregnancy
- Traumatic arrest with > 5 minutes of CPR without return of vital signs
- Brain matter exposed or penetrating brain injury (GSW)
- Isolated drowning or hanging victims
- Objection to study voiced by subject or family member at the scene
- Inability to obtain IV or intraosseous access
- Isolated burns without evidence of traumatic injury
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Whole Blood
Subjects will receive up to two units of whole blood as collected by local blood bank procedures and stored at 1-6 degrees Celsius initiated in the prehospital phase of care. |
low titer whole blood, group O kept to either 21 days or 35 days based upon which preservation process is employed at each respective participating site |
|
Comparateur actif: Component transfusion
Subjects will receive prehospital crystalloid infusion or blood component transfusion resuscitation per site standard care for the respective Emergency Medical unit/service. |
crystalloid infusion or blood component transfusion resuscitation |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
30 Day Mortality
Délai: thru 30 days of enrollment
|
All cause mortality within 30 days |
thru 30 days of enrollment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
3-hour Mortality
Délai: Enrollment through 3 hours
|
Death within 3 hours of enrollment |
Enrollment through 3 hours
|
|
6-hour Mortality
Délai: Enrollment through 6 hours
|
Death within 6 hours of enrollment |
Enrollment through 6 hours
|
|
24-hour Mortality
Délai: Enrollment through 24 hours
|
Death within 24 hours of enrollment |
Enrollment through 24 hours
|
|
In-hospital Mortality
Délai: Enrollment through hospital discharge or 30 days
|
Death prior to hospital discharge |
Enrollment through hospital discharge or 30 days
|
|
Blood and Blood Component Transfusion Amount
Délai: Enrollment through 24 hours
|
Number of units of blood or blood component transfused |
Enrollment through 24 hours
|
|
Multiple Organ Failure (MOF)
Délai: Enrollment through 7 days or ICU discharge
|
Organ dysfunction will be evaluated via the Denver Post-injury Multiple Organ Failure Score. Patients who are never admitted to the Intensive Care Unit (ICU) or those with a length of ICU stay of less than 48 hours will be considered to have a Denver score of 0. A summary of the Denver score may be calculated by summing the worst scores of each of the individual systems over the course of the ICU stay. A summary Denver score > 3 will be classified as MOF. |
Enrollment through 7 days or ICU discharge
|
|
Hospital-acquired Pneumonia
Délai: Number of participants who develop pneumonia through 30 days
|
Pneumonia acquired during hospitalization per Center for Disease Control (CDC) criteria |
Number of participants who develop pneumonia through 30 days
|
|
Blood Stream Infection
Délai: Number of participants who develop blood stream infection through 30 days
|
Blood stream infection during hospitalization per CDC criteria |
Number of participants who develop blood stream infection through 30 days
|
|
Acute Respiratory Distress Syndrome (ARDS)
Délai: Number of participants who develop ARDS through 30 days
|
The Berlin definition for mild ARDS (PaO2/FIO2, ≤ 300 mm Hg + timing, imaging and origin criteria) will be utilized as a threshold value to determine the incidence of ARDS and will be further stratified into Moderate (PaO2/FIO2, ≤ 200 mm Hg) and Severe (PaO2/FIO2, ≤ 100 mm Hg). |
Number of participants who develop ARDS through 30 days
|
|
Abnormal International Normalized Ratio (INR)
Délai: Enrollment through 60 minutes
|
Measurement of platelet hemostatic function |
Enrollment through 60 minutes
|
|
Achievement of Hemostasis
Délai: Enrollment through 4 hours
|
Ability to reach nadir transfusion requirement of 1 unit of red blood cells in a 60-minute time period in the first 4 hours following arrival |
Enrollment through 4 hours
|
|
Transfusion Reaction
Délai: Enrollment through 24 hours
|
Any transfusion complication |
Enrollment through 24 hours
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Jason L Sperry, MD, University of Pittsburgh
Publications et liens utiles
Publications générales
- Brunskill SJ, Disegna A, Wong H, Fabes J, Desborough MJ, Doree C, Davenport R, Curry N, Stanworth SJ. Blood transfusion strategies for major bleeding in trauma. Cochrane Database Syst Rev. 2025 Apr 24;4(4):CD012635. doi: 10.1002/14651858.CD012635.pub2.
- Meizoso JP, Cotton BA, Lawless RA, Kodadek LM, Lynde JM, Russell N, Gaspich J, Maung A, Anderson C, Reynolds JM, Haines KL, Kasotakis G, Freeman JJ. Whole blood resuscitation for injured patients requiring transfusion: A systematic review, meta-analysis, and practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2024 Sep 1;97(3):460-470. doi: 10.1097/TA.0000000000004327. Epub 2024 Mar 27.
- Sperry JL, Guyette FX, Cotton BA, Luther JF, Utarnachitt RB, Kutcher ME, Daley BJ, Peetz AB, Patel MB, Goodman MD, Claridge JA, Patel N, Harbrecht BG, Hashmi ZG, Zarychanski R, Neal MD, Yazer MH, Martin-Gill C, Vincent LE, Harner AM, Meyer DE, Latimer AJ, Robinson BR, McKnight CL, Hinckley WR, Miller KR, Jansen JO, Martin D, Fox EE, Rosario-Rivera BL, Wisniewski SR; TOWAR Study Group. Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage. N Engl J Med. 2026 Jun 18;394(23):2317-2328. doi: 10.1056/NEJMoa2602167. Epub 2026 May 18.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STUDY20110430
- W81XWH-16-D-0024 (Autre subvention/numéro de financement: Department of Defense)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified data may be shared with the funding agency as well as other researchers upon request to the Principal Investigator.
Délai de partage IPD
Data will become available after publication of the primary manuscript.
Critères d'accès au partage IPD
Requests for data will be submitted in writing and reviewed by the Principal Investigator.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .